Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC
@article{Munster2009ClinicalAB, title={Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC}, author={P. Munster and D. Marchion and E. Biçaku and M. Lacevic and J. Kim and B. Centeno and A. Daud and Anthony M Neuger and S. Minton and D. Sullivan}, journal={Clinical Cancer Research}, year={2009}, volume={15}, pages={2488 - 2496} }
Purpose: The aim was to study the biological and molecular effects of the histone deacetylase (HDAC) inhibitor, valproic acid, in patients with solid tumor malignancies. Experimental Design: A phase I dose escalation of valproic acid given on days 1 to 3 followed by epirubicin (day 3) was followed by a dose expansion of valproic acid combined with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC100). Pharmacodynamic and pharmacokinetic studies entailed valproic acid and epirubicin plasma… CONTINUE READING
Figures, Tables, and Topics from this paper
134 Citations
Phase I Pharmacokinetic and Pharmacodynamic Evaluation of Combined Valproic Acid/Doxorubicin Treatment in Dogs with Spontaneous Cancer
- Biology, Medicine
- Clinical Cancer Research
- 2010
- 21
- PDF
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
- Biology, Medicine
- British Journal of Cancer
- 2009
- 138
A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma.
- Medicine
- Annals of oncology : official journal of the European Society for Medical Oncology
- 2016
- 16
Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2017
- 40
Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy.
- Biology, Medicine
- European journal of cancer
- 2010
- 36
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
- Biology, Medicine
- British Journal of Cancer
- 2011
- 279
- PDF
References
SHOWING 1-10 OF 76 REFERENCES
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2007
- 198
Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial
- Biology, Medicine
- British Journal of Cancer
- 2007
- 169
- PDF
Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study
- Biology, Medicine
- Molecular Cancer
- 2005
- 124
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2006
- 403
Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies
- Medicine
- Clinical Cancer Research
- 2007
- 166
- PDF
In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates
- Biology, Medicine
- Molecular Cancer Therapeutics
- 2005
- 72
- PDF
A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies
- Medicine
- Clinical Cancer Research
- 2006
- 293
- PDF
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.
- Medicine
- Blood
- 2007
- 256
A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas
- Medicine
- Clinical Cancer Research
- 2008
- 141
- PDF